Loading...
Loading...
FWBI| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 5,405.9K |
| Operating I/L | -5,405.9K |
| Other Income/Expense | -2.3K |
| Interest Income | 0.9K |
| Pretax | -5,408.1K |
| Income Tax Expense | 2.3K |
| Net Income/Loss | -5,410.4K |
First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of targeted therapies for gastrointestinal diseases. The company's product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and adrulipase, a recombinant lipase enzyme designed to aid in nutrient digestion. Their pipeline includes treatments for severe acute respiratory syndrome coronavirus 2 gastrointestinal infections, ulcerative proctitis, ulcerative proctosigmoiditis, immune checkpoint inhibitor-associated colitis and diarrhea, Crohn's disease, exocrine pancreatic insufficiency in patients with cystic fibrosis, and chronic pancreatitis.
